Related Experiment Videos
Cytokine modified tumor vaccines
Todd D Armstrong1, Elizabeth M Jaffee
1Bunting-Blaustein Cancer Research Building, Room 4M86, Johns Hopkins Medical Institutions, 1650 Orleans Street, Baltimore, MD 21231, USA.
Abstract:
The immune system can recognize tumors, but may be actively tolerized to tumors during the tumorigenesis process. The identity of most tumor antigens remains unknown, but the number is growing due to new techniques. Most clinical trials using genetically modified tumor vaccines have shown immunological responses (DTH), but few clinical responses. Certain chemotherapeutic agents may enhance the immune effects of genetically modified tumor vaccines.
Insights
The immune system can fight tumors, but cancer can suppress this response. New techniques identify tumor antigens, and some therapies may boost anti-tumor immunity.
Area of Science:
- Immunology
- Oncology
- Cancer Research
Background:
- The immune system possesses the capacity for tumor recognition.
- Tumorigenesis can induce active immune tolerance, hindering anti-tumor responses.
- The identification of tumor antigens is expanding due to advancements in technology.
Purpose of the Study:
- To explore the complexities of tumor immunology and immune tolerance.
- To review the current understanding of tumor antigen discovery.
- To assess the clinical efficacy of tumor vaccines and potential synergistic therapies.
Main Methods:
- Review of current literature on tumor immunology and antigen identification.
- Analysis of clinical trial data for genetically modified tumor vaccines.
- Investigation into the immunomodulatory effects of chemotherapeutic agents.
Main Results:
- While tumor vaccines often elicit immune responses like delayed-type hypersensitivity (DTH), clinical responses are infrequent.
- The number of identified tumor antigens is increasing with novel techniques.
- Certain chemotherapeutic agents demonstrate potential to augment the immune effects of tumor vaccines.
Conclusions:
- Despite immune recognition, tumors can evade immune surveillance through active tolerance.
- Advancements in tumor antigen identification are crucial for developing targeted therapies.
- Combination strategies involving tumor vaccines and specific chemotherapeutics may improve clinical outcomes by enhancing anti-tumor immunity.